HOUSTON, Dec. 9, 2021 /PRNewswire/ -- Marker Therapeutics,
Inc. (NASDAQ: MRKR), a clinical-stage immuno-oncology company
specializing in the development of next-generation T cell-based
immunotherapies for the treatment of hematological malignancies and
solid tumor indications, today announced the appointment of
Katharine Knobil, M.D., to the
Company's Board of Directors.
"We are excited to announce the appointment of Dr. Knobil to the
Board of Directors," said Peter L.
Hoang, President & CEO of Marker. "Dr. Knobil's
extensive leadership experience in clinical development of new
therapies, including 20 years of leadership at GlaxoSmithKline plc,
will serve Marker well as the Company advances its novel cell
therapies in the clinic. We look forward to Dr. Knobil's valuable
counsel and expertise."
Dr. Knobil currently serves as Chief Medical Officer at Agilent
Technologies, Inc. Prior to Agilent, she served as Chief Medical
Officer and Head of Research and Development at Kaleido
Biosciences, Inc. Previously, Dr. Knobil served in various
leadership positions during a 20-year career at GlaxoSmithKline
plc, before becoming Chief Medical Officer. Dr. Knobil received a
B.A. in Biological Sciences from Cornell
University and an M.D. from the University of Texas Southwestern. She currently
serves on the Board of Directors of Arena Pharmaceuticals, Inc.
About Marker Therapeutics, Inc.
Marker Therapeutics,
Inc. is a clinical-stage immuno-oncology company specializing in
the development of next-generation T cell-based immunotherapies for
the treatment of hematological malignancies and solid tumor
indications. Marker's cell therapy technology is based on the
selective expansion of non-engineered, tumor-specific T cells that
recognize tumor associated antigens (i.e. tumor targets) and kill
tumor cells expressing those targets. This population of T cells is
designed to attack multiple tumor targets following infusion into
patients and to activate the patient's immune system to produce
broad spectrum anti-tumor activity. Because Marker does not
genetically engineer its T cell therapies, we believe that our
product candidates will be easier and less expensive to
manufacture, with reduced toxicities, compared to current
engineered CAR-T and TCR-based approaches, and may provide patients
with meaningful clinical benefit. As a result, Marker believes its
portfolio of T cell therapies has a compelling product profile, as
compared to current gene-modified CAR-T and TCR-based
therapies.
To receive future press releases via email, please visit:
https://www.markertherapeutics.com/email-alerts.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/marker-therapeutics-appoints-biotech-executive-katharine-knobil-md-to-board-of-directors-301440745.html
SOURCE Marker Therapeutics, Inc.